| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IL17; CTLA8; IL-17; CTLA-8; IL-17A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL17A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL17A抗体的参考文献，包含文献名称、作者及摘要概述：
---
1. **文献名称**：*Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials*
**作者**：Langley RG, et al.
**摘要**：两项III期临床试验(ERASURE和FIXTURE)证实，IL17A单抗secukinumab显著改善中重度斑块型银屑病患者的皮损(PASI评分)，安全性良好，支持其作为一线生物制剂的应用。
2. **文献名称**：*Ixekizumab for the Treatment of Psoriasis: 60-Week Results from UNCOVER-3*
**作者**：Gordon KB, et al.
**摘要**：III期试验UNCOVER-3的60周数据显示，ixekizumab(IL17A抑制剂)在银屑病患者中具有持续疗效，超过80%患者达到PASI 90缓解，长期耐受性良好。
3. **文献名称**：*Secukinumab in Psoriatic Arthritis: Efficacy and Safety through 2 Years*
**作者**：McInnes IB, et al.
**摘要**：针对银屑病关节炎的延长研究表明，secukinumab治疗2年后仍显著缓解关节症状和皮肤病变，不良事件率低，验证IL17A靶点的长期治疗价值。
4. **文献名称**：*IL-17A Inhibition in Ankylosing Spondylitis: A Randomized Controlled Trial*
**作者**：Baeten D, et al.
**摘要**：随机对照试验显示，secukinumab显著改善强直性脊柱炎患者的ASAS40应答率(vs 安慰剂)，证实IL17A通路在该疾病中的关键作用。
---
**备注**：以上文献均聚焦IL17A抗体(如secukinumab、ixekizumab)在自身免疫病中的临床应用，涵盖银屑病、银屑病关节炎及强直性脊柱炎，数据源自关键III期试验或长期随访研究。
IL-17A, a pro-inflammatory cytokine primarily produced by Th17 cells, plays a pivotal role in host defense and autoimmune diseases. It activates downstream signaling via IL-17 receptors, inducing chemokines and antimicrobial peptides that recruit neutrophils and promote inflammation. Dysregulated IL-17A is implicated in chronic inflammatory conditions like psoriasis, psoriatic arthritis, ankylosing spondylitis, and multiple sclerosis.
IL-17A-targeting antibodies emerged as therapeutic agents to block this pathway. These monoclonal antibodies bind IL-17A, preventing its interaction with receptors and interrupting inflammatory cascades. Secukinumab (anti-IL-17A) and ixekizumab (anti-IL-17A) were among the first approved biologics, demonstrating high efficacy in psoriasis by rapidly reducing skin lesions and joint inflammation. Their success validated IL-17A as a key therapeutic target.
Research continues to explore IL-17A's role in other diseases, including inflammatory bowel disease and rheumatoid arthritis, though results vary due to complex cytokine networks. Safety profiles generally favor IL-17A inhibitors over broader immunosuppressants, but risks like candidiasis remain due to impaired mucosal immunity. Ongoing studies aim to optimize dosing, expand indications, and identify biomarkers for personalized treatment. IL-17A antibodies represent a paradigm shift in managing Th17-driven pathologies, balancing targeted action with systemic immune modulation.
×
